The revocation of a Sigma-Aldrich Cas9 patent could be a sign of things to come in other EPO opposition proceedings, but Europe’s CRISPR IP state of play will remain uncertain for several years
The revocation of a Sigma-Aldrich Cas9 patent could be a sign of things to come in other EPO opposition proceedings, but Europe’s CRISPR IP state of play will remain uncertain for several years